Delivery Order SPE2DB22D3016-SPE2DB25FBCY6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,759.95 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets in quantities of 30, with an ultimate completion date of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be performed from the contractor's facility...
- The Defense Logistics Agency awarded a delivery order valued at $1,544.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count package) on July 29, 2025, with completion targeted for July 30, 2025. This competitive award—utilizing firm fixed pricing with no set-aside designation—represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's...
- The Defense Logistics Agency awarded a $18,664.07 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count units) with a completion date of September 11, 2025. This competitive award, issued as a firm fixed-price delivery order with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with the agency. The pharmaceutical product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $5,956.09 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This competitive award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a $8,321.43 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a completion date of June 26, 2025. This competitive award employs a firm fixed price structure with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $6,523.43 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $4,931.21 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- The Defense Logistics Agency awarded a $3,734.63 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Ondansetron ODT 4 mg on July 26, 2025, with completion expected by July 28, 2025. This competitive award, issued under firm fixed pricing, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is located in...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBCY6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,443.61 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under the company's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999.00 IDC with the Defense Logistics Agency (SPE2DX), which runs through December 2026 and serves as a global pharmaceutical support mechanism for military healthcare programs worldwide. As a major pharmaceutical distributor, AmerisourceBergen supplies a full spectrum of medical products including brand-name and generic medications, vaccines, and specialized healthcare commodities to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The Ondansetron order aligns with the company's portfolio of pharmaceutical deliveries across multiple therapeutic domains to federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 7/24/25 |